Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_91
Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . first symptoms (day 5 after first positive sample), C. pre-symptomatic post-peak phase (day 2 after first positive sample) and D. pre-symptomatic pre-peak phase (day 0). Overall, early potent treatment limits duration of infection......
Document: is the (which was not peer-reviewed) The copyright holder for this preprint . first symptoms (day 5 after first positive sample), C. pre-symptomatic post-peak phase (day 2 after first positive sample) and D. pre-symptomatic pre-peak phase (day 0). Overall, early potent treatment limits duration of infection.
Search related documents:
Co phrase search for related documents- early potent treatment and positive sample: 1, 2, 3
- early potent treatment and post peak phase: 1, 2, 3
- early potent treatment and pre peak phase: 1, 2, 3
- infection duration and positive sample: 1, 2, 3, 4, 5
- infection duration and post peak phase: 1, 2, 3
- infection duration and pre peak phase: 1, 2, 3
- positive sample and post peak phase: 1, 2, 3, 4, 5, 6
- positive sample and pre peak phase: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date